MultiVir Clinical Trials Information

Tumor suppressor p53 and IL24 gene abnormalities are among the most common molecular defects in cancers causing tumor progression, treatment resistance and immune suppression.

MultiVir’s Ad-p53 and Ad-IL24 product candidates deliver normal p53 and IL24 genes into tumors to restore their tumor suppressor functions which include inhibition of tumor growth and the activation of anti-tumor immune responses.

Active Clinical Trials

Liver-metases

Planned Clinical Trials

Head-and-Neck

Melanoma